681 Clinical development of STL-101, a personalized TIL therapy for treatment of advance solid tumors
Vincent Chung(City of Hope), Sunil Sharma(Translational Genomics Research Institute), Mohan R. Kaadige(Translational Genomics Research Institute), Stephen J. Forman(City Of Hope National Medical Center), Trason Thode(Translational Genomics Research Institute), Jorge Soria‐Bustos(Translational Genomics Research Institute), Raffaella Soldi(Banner Health), Lud Ng(Translational Genomics Research Institute), Tithi Ghosh-Halder(Translational Genomics Research Institute), John A. Altin(Translational Genomics Research Institute), Erin Kelley(Translational Genomics Research Institute), Alexis Weston(Translational Genomics Research Institute)
Cited by 1
Related Papers
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
|Clinical Cancer Research|2015|754